Reviews Pipeline Therapeutics for Cathepsin L1 by Companies and Universities/Research institutes with the help of latest report

Cathepsin L1 – Pipeline Review, H1 2018, outlays comprehensive information on the Cathepsin L1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Pune, India – March 29, 2018 /MarketersMedia/ —

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) – Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation.
Report Source: https://www.themarketreports.com/report/cathepsin-l1-cathepsin-l-or-major-excreted-protein-or-ctsl-or-ec-342215-pipeline-review-h1-2018
Scope
• The report provides a snapshot of the global therapeutic landscape for Cathepsin L1
• The report reviews Cathepsin L1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Cathepsin L1 targeted therapeutics and enlists all their major and minor projects
• The report assesses Cathepsin L1 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
Purchase this report at: https://www.themarketreports.com/report/buy-now/1036791
List of Tables
• Number of Products under Development by Stage of Development, H1 2018
• Number of Products under Development by Therapy Areas, H1 2018
• Number of Products under Development by Indication, H1 2018
• Number of Products under Development by Companies, H1 2018
• Products under Development by Companies, H1 2018
• Number of Products by Stage and Mechanism of Actions, H1 2018
• Number of Products by Stage and Route of Administration, H1 2018
• Number of Products by Stage and Molecule Type, H1 2018
• Pipeline by Mateon Therapeutics Inc, H1 2018
• Pipeline by Phelix Therapeutics LLC, H1 2018
• Pipeline by Virobay Inc, H1 2018
• Dormant Projects, H1 2018
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1036791

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/reviews-pipeline-therapeutics-for-cathepsin-l1-by-companies-and-universities-research-institutes-with-the-help-of-latest-report/322617

For more information, please visit https://www.themarketreports.com/report/cathepsin-l1-cathepsin-l-or-major-excreted-protein-or-ctsl-or-ec-342215-pipeline-review-h1-2018%20%20

Source: MarketersMedia

Release ID: 322617